Back to Journals » Infection and Drug Resistance » Volume 8

Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics

Authors Zmarlicka M, Nailor M, Nicolau D

Received 9 May 2015

Accepted for publication 8 June 2015

Published 24 August 2015 Volume 2015:8 Pages 297—309


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Suresh Antony

Monika T Zmarlicka,1 Michael D Nailor,2 David P Nicolau3

1Department of Pharmacy, Hartford Hospital, Hartford, 2School of Pharmacy, Department of Pharmacy Practice, University of Connecticut, Storrs, 3Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA

Abstract: Since the first New Delhi metallo-beta-lactamase (NDM) report in 2009, NDM has spread globally causing various types of infections. NDM-positive organisms produce in vitro resistance phenotypes to carbapenems and many other antimicrobials. It is thus surprising that the literature examining clinical experiences with NDM does not report corresponding poor clinical outcomes. There are many instances where good clinical outcomes are described, despite a mismatch between administered antimicrobials and resistant in vitro susceptibilities. Available in vitro data for either monotherapy or combination therapy does not provide an explanation for these observations. However, animal studies do begin to shed more light on this phenomenon. They imply that the in vivo expression of NDM may not confer clinical resistance to all cephalosporin and carbapenem antibiotics as predicted by in vitro testing but other resistance mechanisms need to be present to generate a resistant phenotype. As such, previously abandoned therapies, particularly carbapenems and beta-lactamase inhibitor combinations, may retain utility against infections caused by NDM producers.

Keywords: carbapenemase, metallo-beta-lactamase, resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]